An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 867-874

  Fearon, K C H ^a   Falconer, J S ^a   Ross, J A ^a   Carter, D C ^a   Hunter, J O ^b   Reynolds, P D ^b   Tuffnell, Q ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Essential fatty acids; Gamma linolenic acid; Lithium; Pancreatic cancer

Indexed keywords

GAMMA LINOLENIC ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEMOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MALE; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL MODEL; THROMBOPHLEBITIS;

AGED; ANTINEOPLASTIC AGENTS; FATTY ACIDS; FEMALE; GAMMA-LINOLENIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; LITHIUM; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TIME FACTORS;

EID: 0029896509     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 281: 1589-1591, 1980.
2. Keating JJ, Johnson PJ, Cochrane AMG, et al: A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic cancer. Br J Cancer 60: 789-792, 1989.
3. Bakkevold KE, Pettersen A, Arnasjo B, et al: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surgery 77: 725-730, 1990.
4. Palmer K R, Kerr M, Knowles G, Cull A, Carter DC, Leonard R C F: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surgery 81: 882-885, 1994.
5. Casper ES, Schwartz GK, Johnson B, et al: Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Investigational New Drugs 10: 313-316, 1992.
6. Klijn JGM, Hoff AM, Planting ASTH, et al: Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62: 627-630, 1980.
7. Bukowski RM, Fleming TR, Macdonald JS, et al: Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. Cancer 71: 322-325, 1993.
8. Cullinan S, Moertel CG, Wiesand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65: 2207-2212, 1990.
9. Gastrointestinal Tumor Study Group: Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int J Radiation Oncology Biol Phys 5: 1643-1647, 1979.
10. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253: 2061-2067, 1985.
11. Philip PA, Carmichael J, Tonkin K, et al: Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67: 379-382, 1993.
12. Schifeling DJ, Konski AA, Howard JM, et al: Radiation therapy and 5fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. Int J Pancreatology 12(3): 239-243, 1992.
13. Topham C, Glees J, Rawson NSB, et al: Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer 64: 179-181, 1991.
14. Hansen R, Quebbeman E, Ritch P, et al: Continuous 5-fluorouracil 5FU infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 295(2): 91-93, 1988.
15. Einhorn LH, Loehrer PJ: Ifosfamide chemotherapy for pancreatic carcinoma. Anticancer Drug Research 9: 177-184, 1986.
16. Oster MW, Gray R, Panasci L, et al: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 57: 29-33, 1986.
17. Wong A, Chan A, Arthur K: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treatment Reports 71(7-8): 749-750, 1987.
18. Gonzalez-Barcena D, Ibarra-Olmos MA, Garcia-Carrasco F, et al: Influence of DTrp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed & Pharmacother 43: 313-317, 1989.
19. Andren-Sandberg A: Treatment with an LHRH analogue in patients with advanced pancreatic cancer. Acta Chir Scand 156: 549-551, 1990.
20. Kajanti MJ, Pyhonen SO: Phase II trial of oral carmoflor in advanced pancreatic carcinoma. Ann of Oncology 2: 765-766, 1991.
21. Horrobin DF: Essential fatty acids, lipid peroxidation and cancer. In: Omega-6 essential fatty acids Pathophysiology and roles in clinical medicine (Horrobin, DF, ed). New York, Alan R Liss, 1991, pp351-378.
22. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumour cells and its relationship to lipid peroxidation. J Natl Cancer Inst 80: 188-194, 1988.
23. Dippenaar N, Booyens J, Fahri D, et al: The reversibility of cancer: evidence that malignancy in human hepatoma cells is gamma-linolenic acid deficiency dependent. S Afr Med J 62: 683-685, 1982.
24. Fujiwara F, Todo S, Imashuku S: Antitumor effect of gamma-linolenic acid on cultured human neuroblastoma cells. Prostaglandins Leukotr EFAs 15: 15-34, 1984.
25. Begin ME, Das UN, Ells G: Cytotoxic effects of essential fatty acids in mixed cultures of normal and malignant human cells. Prog Lipid Res 25: 573-576, 1986.
26. Begin ME: Effects of polyunsaturated fatty acids and of their oxidation products on cell survival. Chem Phys Lipids 45: 269-313, 1987.
27. -6 polyunsaturated fatty acids. J Natl Cancer Inst 77: 1053-1062, 1986.
28. 1 on the proliferation of human osteogenic sarcoma cells in culture. Prostaglandins Leukotrienes Med 15: 15-33, 1984.
29. Hayashi Y, Fukushima S, Hirata T, et al: Anticancer activity of free gammalinolenic acid and the effects of serum albumin an anticancer activity of gamma-linolenic acid in vitro. J Pharmacobio-Dyn 13: 705-711, 1990.
30. 1 on three human colon carcinoma cell lines. Prostaglandins Leukotr EFAs 47: 313-319, 1992.
31. Ghayur T, Horrobin DF: Effects of essential fatty acids in the form of evening primrose oil on the growth of the rat R3230AC transplantable mammary tumour. IRCS J Med Sci 9: 582, 1981.
32. Karmali RA, Marsh J, Fuchs C: Effects of dietary enrichment with gammalinolenic acid upon the growth of the R3230AC mammary adenocarcinoma. J Nutr Growth Cancer 2: 41-51, 1985.
33. Abou El-Ela SH, Prasse KW, Carroll R, et al: Eicosanoid synthesis in 7,12dimethylbenz(a)anthracene-induced mammary carcinomas in Sprague-Dawley rats fed primrose oil, menhaden oil, or corn oil diet. Lipids 23: 948-954, 1988.
34. Pritchard GA, Jones DL, Mansel RE: Lipids in breast carcinogenesis. Br J Surg 76; 1069-1073, 1989.
35. Gonzalez MJ, Schemmel RA, Gray JI, et al: Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis 12(7): 1231-1235, 1991.
36. Casper ES: Pancreatic cancer: how can we progress? Eur J Cancer 29A: 171-172, 1993.